Enhancement of bioavailability of cefpodoxime proxetil using different polymeric microparticles.
Poorly water-soluble drugs such as cefpodoxime proxetil (400 μg/ml) offer a challenging problem in drug formulation as poor solubility is generally associated with poor dissolution characteristics and thus poor oral bioavailability. According to these characteristics, preparation of cefpodoxime proxetil microparticle has been achieved using high-speed homogenization. Polymers (methylcellulose, sodium alginate, and chitosan) were precipitated on the surface of cefpodoxime proxetil using sodium citrate and calcium chloride as salting-out agents. The pure drug and the prepared microparticles with different concentrations of polymer (0.05-1.0%) were characterized in terms of solubility, drug content, particle size, thermal behavior (differential scanning calorimeter), surface morphology (scanning electron microscopy), in vitro drug release, and stability studies. The in vivo performance was assessed by pharmacokinetic study. The dissolution studies demonstrate a marked increase in the dissolution rate in comparison with pure drug. The considerable improvement in the dissolution rate of cefpodoxime proxetil from optimized microparticle was attributed to the wetting effect of polymers, altered surface morphology, and micronization of drug particles. The optimized microparticles exhibited excellent stability on storage at accelerated condition. The in vivo studies revealed that the optimized formulations provided improved pharmacokinetic parameter in rats as compared with pure drug. The particle size of drug was drastically reduced during formulation process of microparticles.
Khan
Fahim
F
School of Pharmaceutical Sciences, Rajive Gandhi Technical University, Airport Bypass Road, Gandhi Nagar, Bhopal, Madhya Pradesh, 462036, India.
Katara
Rajesh
R
Ramteke
Suman
S
D000818:Animals; D001682:Biological Availability; D002214:Capsules / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D015296:Ceftizoxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D004355:Drug Stability; D006801:Humans; D008297:Male; D008863:Microspheres; D010316:Particle Size; D011108:Polymers / Q000737:chemistry*; D051381:Rats; D017208:Rats, Wistar; D000097627:Cefpodoxime Proxetil
D002214:Capsules; D015296:Ceftizoxime; D011108:Polymers; D000097627:Cefpodoxime Proxetil
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 1;835(1-2):16-20
16517228
Int J Pharm. 2003 Mar 26;254(2):137-45
12623189
Pharm Res. 1995 Mar;12(3):413-20
7617530
Int J Pharm. 2006 Jul 24;317(2):155-60
16621365
Antimicrob Agents Chemother. 1992 Apr;36(4):796-800
1354432
Int J Pharm. 1997 Nov 28;157(2):153-161
10477812
Eur J Pharm Sci. 2000 Dec;12(2):103-10
11102737
Eur J Pharm Biopharm. 2006 Oct;64(2):255-9
16797950
Antimicrob Agents Chemother. 1998 Oct;42(10):2602-6
9756762
Int J Pharm. 2008 Feb 28;350(1-2):279-90
17945447
Int J Pharm. 2007 May 4;336(1):42-8
17157459
Int J Pharm. 2002 Mar 2;234(1-2):1-17
11839433
Med Princ Pract. 2007;16(5):355-9
17709923